内分泌激素：彻底改变 2 型糖尿病和肥胖症肝肾疾病的治疗格局。

IF 3.2 3区医学

Journal of Diabetes Investigation Pub Date : 2024-10-26 DOI:10.1111/jdi.14336

Jae Hyun Bae, Young Min Cho

引用次数: 0

摘要

目前正在进行的几项试验正在评估以增量素为基础的疗法（包括 GLP-1 受体激动剂）对 CKD 和 MASLD 的影响。这些研究将有助于深入了解它们治疗 2 型糖尿病和肥胖症患者代谢性疾病的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity.

Several ongoing trials are evaluating incretin-based therapies, including GLP-1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in people with type 2 diabetes and obesity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Diabetes Investigation Medicine-Internal Medicine

自引率

9.40%

发文量

218

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).